Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.
Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC). To assess trends and disparities in next-generation sequencing (NGS) …